Rankings
▼
Calendar
COLL Q4 2023 Earnings — Collegium Pharmaceutical, Inc. Revenue & Financial Results | Market Cap Arena
COLL
Collegium Pharmaceutical, Inc.
$1B
Q4 2023 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$150M
+15.5% YoY
Gross Profit
$95M
63.2% margin
Operating Income
$62M
41.2% margin
Net Income
$32M
21.3% margin
EPS (Diluted)
$0.82
QoQ Revenue Growth
+9.5%
Cash Flow
Operating Cash Flow
$73M
Free Cash Flow
$73M
Stock-Based Comp.
$7M
Balance Sheet
Total Assets
$1.1B
Total Liabilities
$948M
Stockholders' Equity
$195M
Cash & Equivalents
$239M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$150M
$130M
+15.5%
Gross Profit
$95M
$50M
+90.1%
Operating Income
$62M
$12M
+424.7%
Net Income
$32M
-$7M
+543.7%
Revenue Segments
Belbuca
$95M
33%
Xtampza ER
$88M
31%
Nucynta IR
$52M
18%
Nucynta ER
$42M
15%
Symproic
$9M
3%
← FY 2023
All Quarters
Q1 2024 →